Combining semiconductor-based sequencing with amplicon-based cancer gene panels: A rapid next-gen approach to clinical cancer genotyping. Christopher L.

Slides:

Advertisements

Similar presentations

Next-Generation Sequencing: Methodology and Application

Advertisements

High Throughput Donor Plasma NAT Screening Assay Applied to Acute HIV Detection in a Public Health Setting December 5, 2007 Josh Goldsmith, Ph.D. National.

The State of the Art - Ion RoadMap Update

FOUNDER, SCIENTIFIC DIRECTOR

Validation of BRCA2 mutation scanning using the LightScanner system for high resolution melt analysis Lewis Darnell Nottingham Regional Molecular Genetics.

Next-generation sequencing

The 454 and Ion PGM at the Genomics Core Facility Dr. Deborah Grove, Director for Genetic Analysis Genomics Core Facility Huck Institutes of the Life Sciences.

The Challenges Of Sequencing FFPE DNA Using NGS

Molecular Testing of lung cancer in routine practice

Heinrich & Corless Laboratories GIST Research Updates: May 2012.

Analysis of Norwegian BRCA mutations using Sequenom MALDI TOF MS Ann Curtis on behalf of James Eden Institute of Human Genetics Newcastle University.

Considerations for Analyzing Targeted NGS Data Introduction Tim Hague, CTO.

The LightScanner ® System Achieve High Throughput Mutation Discovery and Genotyping.

Genomics – Next-Gen sequencing and Microarrays

Assay Development Breakout (red) Who was in the room? About half of attendees are active NGS users N=1 doing whole genome analyses Everyone else doing.

Investigating the use of Multiple Displacement Amplification (MDA) to amplify nanogram quantities of DNA to use for downstream mutation screening by sequencing.

HaloPlexHS Get to Know Your DNA. Every Single Fragment.

Genetic Cancer Susceptibility (GCS) Genomics in I4C James McKay.

1. Ion Proton I well Ion 300 series well 454 Titanium well.

The world leader in serving science Sanger sequencing using Ion AmpliSeq™ primers and libraries Stephen Jackson, Ph.D. Associate Director, Product Applications.

A comparison of somatic mutation callers in breast cancer samples and matched blood samples THOMAS BRETONNET BIOINFORMATICS AND COMPUTATIONAL BIOLOGY UNIT.

Research Techniques Made Simple: Next-Generation Sequencing:

Detection of FLT3 Internal Tandem Duplication in Targeted, Short-Read-Length, Next- Generation Sequencing Data David H. Spencer, Haley J. Abel, Christina.

Genomon a high-integrity pipeline for cancer genome and transcriptome sequence analysis Kenichi Chiba(1), Yuichi Shiraishi(1), Ai Okada(1), Hiroko.

Ultra-Deep Sequencing of Multiplex-PCR Enriched Hotspot and

Olga Jarinova, PhD, FCCMG

Cancer Genomics Core Lab

Introduction to GENDX HLA typing products

Delivering a Pharmacogenomics NGS service in 5 working days

Multiplexed Elimination of Wild-Type DNA and High-Resolution Melting Prior to Targeted Resequencing of Liquid Biopsies I. Ladas, M. Fitarelli-Kiehl, C.

Comparison of Clinical Targeted Next-Generation Sequence Data from Formalin-Fixed and Fresh-Frozen Tissue Specimens David H. Spencer, Jennifer K. Sehn,

Molecular Diagnostic Profiling of Lung Cancer Specimens with a Semiconductor-Based Massive Parallel Sequencing Approach Volker Endris, Roland Penzel,

Crystal digital PCR for detection and quantification of circulating EGFR mutations in advanced non-small cell lung cancer Cécile Jovelet Postdocoral fellow.

California Department of Justice – Jan Bashinski DNA Laboratory

DNA Extraction of Lung Cancer Samples for Advanced Diagnostic Testing

Reverse Complement PCR: fast, low cost amplicon based NGS

Carol Beadling, Tanaya L. Neff, Michael C

Content and Labeling of Tests Marketed as Clinical “Whole-Exome Sequencing” Perspectives from a cancer genetics clinician and clinical lab director Allen.

A Targeted High-Throughput Next-Generation Sequencing Panel for Clinical Screening of Mutations, Gene Amplifications, and Fusions in Solid Tumors Rajyalakshmi.

Assessing Copy Number Alterations in Targeted, Amplicon-Based Next-Generation Sequencing Data Catherine Grasso, Timothy Butler, Katherine Rhodes, Michael.

Gastrointestinal Stromal Tumors: Disease and Treatment Update

Reliable Next-Generation Sequencing of Formalin-Fixed, Paraffin-Embedded Tissue Using Single Molecule Tags Astrid Eijkelenboom, Eveline J. Kamping, Annemiek.

Detection of FLT3 Internal Tandem Duplication in Targeted, Short-Read-Length, Next- Generation Sequencing Data David H. Spencer, Haley J. Abel, Christina.

Rosie Coates-Brown Final year Bioinformatics trainee

The characterisation of mtDNA deletions using long-read sequencing

DNA Polymorphisms: DNA markers a useful tool in biotechnology

Plasmid-Based Materials as Multiplex Quality Controls and Calibrators for Clinical Next- Generation Sequencing Assays David J. Sims, Robin D. Harrington,

Clinical Relevance of Sensitive and Quantitative STAT3 Mutation Analysis Using Next- Generation Sequencing in T-Cell Large Granular Lymphocytic Leukemia

Molecular Diagnosis of Autosomal Dominant Polycystic Kidney Disease Using Next- Generation Sequencing Adrian Y. Tan, Alber Michaeel, Genyan Liu, Olivier.

A Comprehensive Strategy for Accurate Mutation Detection of the Highly Homologous PMS2 Jianli Li, Hongzheng Dai, Yanming Feng, Jia Tang, Stella Chen,

High throughput genome study to identify predictors of aggressiveness in patients with sporadic desmoid tumor who undergo a wait and see approach Chiara.

Study of Preanalytic and Analytic Variables for Clinical Next-Generation Sequencing of Circulating Cell-Free Nucleic Acid Meenakshi Mehrotra, Rajesh.

Technical advances in plasma genomic biomarkers

High-Throughput and Sensitive Quantification of Circulating Tumor DNA by Microfluidic- Based Multiplex PCR and Next-Generation Sequencing Yinghui Guan,

Validation and Implementation of a Custom Next-Generation Sequencing Clinical Assay for Hematologic Malignancies Michael J. Kluk, R. Coleman Lindsley,

Multiplex Mutation Screening by Mass Spectrometry

Study of Preanalytic and Analytic Variables for Clinical Next-Generation Sequencing of Circulating Cell-Free Nucleic Acid Meenakshi Mehrotra, Rajesh.

Multiplex Amplification Coupled with COLD-PCR and High Resolution Melting Enables Identification of Low-Abundance Mutations in Cancer Samples with Low.

Analytical Validation of Clinical Whole-Genome and Transcriptome Sequencing of Patient-Derived Tumors for Reporting Targetable Variants in Cancer Kazimierz.

Comparison of Next-Generation Sequencing Panels and Platforms for Detection and Verification of Somatic Tumor Variants for Clinical Diagnostics Maksym.

Gastrointestinal Stromal Tumors: Disease and Treatment Update

Cancer WGS Analytical Pipeline Validation

Multiplex Amplification Coupled with COLD-PCR and High Resolution Melting Enables Identification of Low-Abundance Mutations in Cancer Samples with Low.

Coexistence of Tyrosine Kinase Inhibitor-Sensitizing and Resistant EGFR Mutations in an Untreated Lung Adenocarcinoma Patient and Response to Erlotinib

The Right Tool for the Job: Two Platforms for Targeted DNA Sequencing

A Platform for Rapid Detection of Multiple Oncogenic Mutations With Relevance to Targeted Therapy in Non–Small-Cell Lung Cancer Zengliu Su, Dora Dias-Santagata,

Novel Method for PIK3CA Mutation Analysis

Clinical Validation of a Next-Generation Sequencing Screen for Mutational Hotspots in 46 Cancer-Related Genes Rajesh R. Singh, Keyur P. Patel, Mark J.

TS Tumor Panel (15 Genes) Overview

Rapid Detection of HIV-1 subtype C Integrase resistance mutations by the Use of High-Resolution Melting Analysis Tendai Washaya BSc, Msc. Pre-PhD Student.

Presentation transcript:

Combining semiconductor-based sequencing with amplicon-based cancer gene panels: A rapid next-gen approach to clinical cancer genotyping. Christopher L. Corless, Tanaya Neff, Michael C. Heinrich, Carol Beadling Knight Cancer Institute, Oregon Health & Science University, and Portland Veteran's Affairs Medical Center, Portland, Oregon Background: Bringing next-gen sequencing into clinical (CLIA- licensed) laboratories is an important step in the advancement of personalized cancer care. We have validated a new semiconductor –based sequencing approach (Ion Torrent PGM) in combination with amplicon-based library preparations. Using FFPE-derived samples of tumor and normal DNA, the performance of two panels has been examined in detail: 1) the AmpliSeq Cancer Panel (available from Ion Torrent); 2) a custom panel designed for genotyping GI stromal tumors (GISTs). Designed to detect hotspot mutations across 46 genes. Samples tested: 45 FFPE solid tumors previously genotyped on Sequenom MassArray system, including : - 53 point mutations - 19 in/dels (4 – 63 bp) Input DNA: 10 ng 190 primer pairs (1 tube) 13.3 kb of target sequence Barcoded samples 4 samples per 316 chip Results On-target reads: 95% Average read length:76 bp Average read depth: 2000 (range 8 – 4,948) All 53 point mutations were identified. All 19 in/dels were visible in the sequence, but most were not accurately identified by the Torrent Suite software (version 2.0). Using a cut-off of 8% mutant allele, the sensitivity for known mutations was 100% and the specificity was 92%. There were 27 new non-synonymous mutations with >8% mutant allele frequency detected in regions not covered by the mass spectrometry-based panel, including 24 point mutations and 3 deletions of 2 bp; all 27 were confirmed by Sanger sequence analysis. Conclusions: Combining solid-state sequencing with a highly multiplexed PCR method for library construction is a rapid (48 hr) approach for next-gen sequencing of clinical cancer samples. The protocol requires very little DNA (10-20 ng). Indeed, two DNA samples from laser-captured tumor yielded excellent data with the AmpliSeq Cancer Panel. The process is highly scalable and larger, cancer-specific amplicon panels are in development. Automated identification of in/dels remains a challenge in next-gen sequencing output. Recent improvements in the library preparation protocol and in the variant caller software are leading to further reductions in turn-around time and the number of background variants. Both the Cancer Gene Panel and the GIST Panel are now available in our CLIA-licensed/CAP-accredited laboratory. Acknowledgements: We are grateful for the help of our collaborators at Ion Torrent, including Katherine Rhodes, Michael Thornton, John Leamon and Mark Andersen. ABL1FGFR3NRAS AKT1FLT3PDGFRA ALKGNASPIK3CA APCHNF1APTEN ATMHRASPTPN11 BRAFIDH1RB1 CDH1JAK2RET CDKN2AJAK3SMAD4 CSF1RKDRSMARCB1 CTNNB1KITSMO EGFRKRASSRC ERBB2METSTK11 ERBB4MLH1TP53 FBXW7MPLVHL FGFR1NOTCH1 FGFR2NPM1 AKT1KRASSDHA AKT2MAP2K1SDHAF1 AKT3NF1SDHAF2 ATMNRASSDHB BRAFPDGFRASDHC CDKN2APIK3CASDHD HRASPTENTP53 KITPTPN11 AmpliSeq Cancer Gene Panel (Ion Torrent) Reads per amplicon (Mean + standard dev.) Reads per amplicon (Mean + standard dev.) Comparison of allele ratios: MassArray vs AmpliSeq 53 Point Mutations R=0.92, P< Custom GI Stromal Tumor (GIST) Panel AmpliSeq Cancer Gene Panel (Ion Torrent) Input DNA: 20 ng 477 primer pairs (2 tubes) Amplicons tiled for whole gene coverage 125 to 175 bp amplicons 49.1 kb of target sequence Barcoded samples Primers were designed with the assistance of collaborators at Ion Torrent using the Ion AmpliSeq designer software v1.0. Samples tested: 19 FFPE GISTs that were previously shown to be negative for KIT and PDGFRA mutations. 8 barcoded samples run on a single 318 chip, yielding an average of 337,000 reads per sample 11 barcoded samples run on 316 chips 4 per chip), yielding an average of 392,000 reads per sample Results On-target reads: 88% Average read length: 86 bp Average read depth: 695 (range 11 – 1,848) An NRAS Q61L mutation was confirmed in one case; this mutation is novel in GIST Knight Diagnostic Laboratories